Figure 4.

Initial high vector dose reduces the re-administration efficacy of IS pretreatments

(A) Schematic outline of IS pretreatment regimens and AAV8 dosing. (B) CD8⁺ T cell response to the OVA transgene at 4 weeks post-AAV8-OVA administration (n = 5–10/group). (C) Circulating plasma levels of OVA at 4 weeks post-AAV8-OVA administration. AAV8 capsid-specific IgM (D) and IgG2c (E) Ab levels in plasma samples collected at different time points before re-administration. AAV8 capsid-specific IgM (F) and IgG2c (G) Ab levels in plasma samples collected post-re-administration. (H) Circulating human FIX levels at 4 weeks post-re-administration with AAV8-hFIX. Statistical significance was calculated by one-way ANOVA (Dunnett’s multiple comparisons) for (B), (C), and (H), and two-way ANOVA for (D)–(G). ∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗∗p ≤ 0.0001.